Patient Experience With Once-daily Deutetrabenazine Extended-release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use

Real-world Use of Deutetrabenazine Reduces Tardive Dyskinesia Severity and Improves Quality of Life: Patient-reported Outcomes in the IMPACT-TD Study

Real-world Persistence in Patients with Tardive Dyskinesia: A Comparative Study of Valbenazine and Deutetrabenazine XR

A Genetic Triple Play: Adolescent-onset Hyperkinetic Syndrome with Multilocus KMT2B and FGF14 Variants and Familial Hunter Syndrome in One Pedigree